{"id":1277,"date":"2018-05-04T15:42:12","date_gmt":"2018-05-04T15:42:12","guid":{"rendered":"http:\/\/blog.valuengine.com\/?p=1277"},"modified":"2018-05-04T19:40:58","modified_gmt":"2018-05-04T19:40:58","slug":"valuengine-weekly-medical-stocks-disney-valuations-and-more","status":"publish","type":"post","link":"http:\/\/blog.valuengine.com\/index.php\/valuengine-weekly-medical-stocks-disney-valuations-and-more\/","title":{"rendered":"ValuEngine Weekly: Medical Stocks, Disney, Valuations, and More"},"content":{"rendered":"

NYSE:DIS<\/company:symbol> NASDAQ:ENTA<\/company:symbol> NASDAQ:AXGN<\/company:symbol> NASDAQ:NKTR<\/company:symbol> NASDAQ:CASI<\/company:symbol><\/p>\n

This week, we provide top-five ranked VE data for our Medical Sector stocks. We take a look at our latest data on Disney $DIS and provide a free download link for our stock report on the company. <\/strong><\/span><\/p>\n

VALUATION WATCH: Overvalued stocks now make up 46.74% of our stocks assigned a valuation and 16.69% of those equities are calculated to be overvalued by 20% or more. Nine sectors are calculated to be overvalued.<\/strong><\/span><\/p>\n

ValuEngine Index Overview <\/strong><\/h1>\n\n\n\n\n\n\n\n
Index<\/td>\nWeek Open<\/td>\nFriday PM<\/td>\nChange<\/td>\n% Change<\/td>\nYTD<\/td>\n<\/tr>\n
DJIA<\/strong><\/td>\n24410.41<\/td>\n24150.94<\/td>\n-259.47<\/td>\n-1.06%<\/td>\nN\/A<\/td>\n<\/tr>\n
NASDAQ<\/strong><\/td>\n7133.95<\/td>\n7172.67<\/td>\n38.72<\/td>\n0.54%<\/td>\nN\/A<\/td>\n<\/tr>\n
RUSSELL 2000<\/strong><\/td>\n1556.24<\/td>\n1555.54<\/td>\n-0.70<\/td>\n-0.04%<\/td>\nN\/A<\/td>\n<\/tr>\n
S&P 500<\/strong><\/td>\n2682.51<\/td>\n2649.75<\/td>\n-32.76<\/td>\n-1.22%<\/td>\nN\/A<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

ValuEngine Market Overview <\/strong><\/h1>\n\n\n\n\n\n\n\n
Summary of VE Stock Universe<\/td>\n<\/tr>\n
Stocks Undervalued <\/strong><\/td>\n53.26%<\/td>\n<\/tr>\n
Stocks Overvalued <\/strong><\/td>\n46.74%<\/td>\n<\/tr>\n
Stocks Undervalued by 20% <\/strong><\/td>\n19.41%<\/td>\n<\/tr>\n
Stocks Overvalued by 20% <\/strong><\/td>\n16.69%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

ValuEngine Sector Overview<\/strong><\/h1>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Sector<\/td>\nChange<\/td>\nMTD<\/td>\nYTD<\/td>\nValuation<\/td>\nLast 12-MReturn<\/td>\nP\/E Ratio<\/td>\n<\/tr>\n
Aerospace<\/a><\/td>\n0.06%<\/td>\n-1.47%<\/td>\n2.96%<\/td>\n12.34% overvalued<\/td>\n16.77%<\/td>\n23.55<\/td>\n<\/tr>\n
Computer and Technology<\/a><\/td>\n-0.46%<\/td>\n0.64%<\/td>\n0.85%<\/td>\n11.67% overvalued<\/td>\n22.23%<\/td>\n30.65<\/td>\n<\/tr>\n
Medical<\/a><\/td>\n-0.65%<\/td>\n0.68%<\/td>\n3.54%<\/td>\n4.81% overvalued<\/td>\n33.69%<\/td>\n27.84<\/td>\n<\/tr>\n
Business Services<\/a><\/td>\n-0.07%<\/td>\n0.73%<\/td>\n5.38%<\/td>\n3.42% overvalued<\/td>\n14.35%<\/td>\n23.90<\/td>\n<\/tr>\n
Utilities<\/a><\/td>\n0.43%<\/td>\n1.71%<\/td>\n-3.31%<\/td>\n3.29% overvalued<\/td>\n2.50%<\/td>\n22.35<\/td>\n<\/tr>\n
Consumer Discretionary<\/a><\/td>\n-0.48%<\/td>\n-0.14%<\/td>\n-2.74%<\/td>\n2.61% overvalued<\/td>\n14.00%<\/td>\n25.98<\/td>\n<\/tr>\n
Retail-Wholesale<\/a><\/td>\n-0.76%<\/td>\n-0.53%<\/td>\n-3.51%<\/td>\n2.36% overvalued<\/td>\n11.27%<\/td>\n23.83<\/td>\n<\/tr>\n
Multi-Sector Conglomerates<\/a><\/td>\n-0.45%<\/td>\n-0.55%<\/td>\n-4.74%<\/td>\n0.38% overvalued<\/td>\n6.68%<\/td>\n24.10<\/td>\n<\/tr>\n
Finance<\/a><\/td>\n-0.45%<\/td>\n-0.50%<\/td>\n-1.22%<\/td>\n0.03% overvalued<\/td>\n7.63%<\/td>\n17.59<\/td>\n<\/tr>\n
Consumer Staples<\/a><\/td>\n-0.57%<\/td>\n-1.61%<\/td>\n-5.61%<\/td>\n1.05% undervalued<\/td>\n9.70%<\/td>\n24.07<\/td>\n<\/tr>\n
Construction<\/a><\/td>\n-0.28%<\/td>\n-0.33%<\/td>\n-0.43%<\/td>\n2.94% undervalued<\/td>\n15.88%<\/td>\n22.20<\/td>\n<\/tr>\n
Industrial Products<\/a><\/td>\n-0.54%<\/td>\n-1.23%<\/td>\n-3.89%<\/td>\n3.07% undervalued<\/td>\n11.16%<\/td>\n23.12<\/td>\n<\/tr>\n
Transportation<\/a><\/td>\n0.32%<\/td>\n0.65%<\/td>\n-2.93%<\/td>\n3.99% undervalued<\/td>\n16.89%<\/td>\n20.53<\/td>\n<\/tr>\n
Basic Materials<\/a><\/td>\n-0.55%<\/td>\n-0.22%<\/td>\n0.59%<\/td>\n4.80% undervalued<\/td>\n4.50%<\/td>\n23.72<\/td>\n<\/tr>\n
Auto-Tires-Trucks<\/a><\/td>\n-0.72%<\/td>\n0.06%<\/td>\n-7.36%<\/td>\n9.68% undervalued<\/td>\n9.53%<\/td>\n12.96<\/td>\n<\/tr>\n
Oils-Energy<\/a><\/td>\n-0.85%<\/td>\n-0.55%<\/td>\n2.34%<\/td>\n10.79% undervalued<\/td>\n5.59%<\/td>\n25.53<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Want to learn more about ValuEngine? Our methods? Our history? <\/strong><\/span>
\n Check out our video presentation HERE<\/a><\/strong><\/span><\/p>\n

 <\/p>\n

Sector Talk–Medical <\/strong><\/h1>\n

Below, we present the latest data on Medical stocks from our Professional Stock Analysis Service<\/a>. <\/strong>Top- five lists are provided for each category.\u00a0 We applied some basic liquidity criteria–share price greater than $3 and average daily volume in excess of 100k shares.<\/p>\n

Top-Five Medical Stocks–Short-Term Forecast Returns<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Ticker<\/strong><\/td>\nName<\/strong><\/td>\nMkt Price<\/strong><\/td>\nValuation (%)<\/strong><\/td>\nLast 12-M Return<\/strong> (%)<\/strong><\/td>\n<\/tr>\n
ENTA<\/td>\nENANTA PHARMA<\/td>\n98.49<\/td>\n156.20%<\/td>\n217.61%<\/td>\n<\/tr>\n
AXGN<\/td>\nAXOGEN CORP<\/td>\n41.5<\/td>\n174.80%<\/td>\n237.40%<\/td>\n<\/tr>\n
NKTR<\/td>\nNEKTAR THERAP<\/td>\n82.75<\/td>\n285.06%<\/td>\n349.97%<\/td>\n<\/tr>\n
CASI<\/td>\nCASI PHARMACEUT<\/td>\n7.67<\/td>\n300.00%<\/td>\n578.76%<\/td>\n<\/tr>\n
VCEL<\/td>\nVERICEL CORP<\/td>\n13.05<\/td>\n187.43%<\/td>\n397.14%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Top-Five Medical Stocks–Momentum<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Ticker<\/strong><\/td>\nName<\/strong><\/td>\nMkt Price<\/strong><\/td>\nValuation (%)<\/strong><\/td>\nLast 12-M Return<\/strong> (%)<\/strong><\/td>\n<\/tr>\n
CDNA<\/td>\nCAREDX INC<\/td>\n10.5<\/td>\n93.38%<\/td>\n1106.90%<\/td>\n<\/tr>\n
MRTX<\/td>\nMIRATI THERAPTC<\/td>\n33.75<\/td>\n74.45%<\/td>\n723.17%<\/td>\n<\/tr>\n
MDGL<\/td>\nMADRIGAL PHARMA<\/td>\n112.08<\/td>\n-4.03%<\/td>\n595.72%<\/td>\n<\/tr>\n
CASI<\/td>\nCASI PHARMACEUT<\/td>\n7.67<\/td>\n300.00%<\/td>\n578.76%<\/td>\n<\/tr>\n
QURE<\/td>\nUNIQURE BV<\/td>\n29.14<\/td>\n95.40%<\/td>\n462.55%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Top-Five Medical Stocks–Most Overvalued<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Ticker<\/strong><\/td>\nName<\/strong><\/td>\nMkt Price<\/strong><\/td>\nValuation (%)<\/strong><\/td>\nLast 12-M Return<\/strong> (%)<\/strong><\/td>\n<\/tr>\n
CASI<\/td>\nCASI PHARMACEUT<\/td>\n7.67<\/td>\n300.00%<\/td>\n578.76%<\/td>\n<\/tr>\n
IMMU<\/td>\nIMMUNOMEDICS<\/td>\n18.05<\/td>\n300.00%<\/td>\n231.80%<\/td>\n<\/tr>\n
NKTR<\/td>\nNEKTAR THERAP<\/td>\n82.75<\/td>\n285.06%<\/td>\n349.97%<\/td>\n<\/tr>\n
LJPC<\/td>\nLA JOLLA PHARMA<\/td>\n30.06<\/td>\n255.67%<\/td>\n8.36%<\/td>\n<\/tr>\n
SAGE<\/td>\nSAGE THERAPEUTC<\/td>\n148.13<\/td>\n210.80%<\/td>\n116.19%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Free Download for Readers<\/strong><\/h1>\n

As a bonus to our Free Weekly Newsletter subscribers,
\nwe are offering a FREE DOWNLOAD of one of our Stock Reports<\/strong><\/em><\/p>\n

The Walt Disney Company (DIS), together with its subsidiaries and affiliates, is a leading diversified international family entertainment and media enterprise with five business segments: media networks, parks and resorts, studio entertainment, consumer products and interactive media.<\/p>\n

VALUENGINE RECOMMENDATION: ValuEngine continues its SELL recommendation on Walt Disney Company for 2018-05-03. Based on the information we have gathered and our resulting research, we feel that Walt Disney Company has the probability to UNDERPERFORM average market performance for the next year. The company exhibits UNATTRACTIVE Book Market Ratio and Momentum.<\/p>\n

You can download a free copy of detailed report on The Walt Disney Company (DIS) from the link below.<\/p>\n

R<\/strong><\/em>ead our Complete Rating and Forecast Report <\/strong><\/em>HERE.<\/strong><\/a><\/p>\n

<\/p>\n\n\n\n\n\n\n\n\n\n\n
ValuEngine Forecast<\/strong><\/td>\n<\/tr>\n
<\/td>\nTarget
\nPrice*<\/th>\n		Expected
\nReturn<\/th>\n<\/tr>\n
1-Month<\/strong><\/td>\n98.11<\/td>\n-0.66%<\/td>\n<\/tr>\n
3-Month<\/strong><\/td>\n97.98<\/td>\n-0.79%<\/td>\n<\/tr>\n
6-Month<\/strong><\/td>\n94.73<\/td>\n-4.08%<\/td>\n<\/tr>\n
1-Year<\/strong><\/td>\n90.97<\/td>\n-7.89%<\/td>\n<\/tr>\n
2-Year<\/strong><\/td>\n95.53<\/td>\n-3.27%<\/td>\n<\/tr>\n
3-Year<\/strong><\/td>\n99.35<\/td>\n0.60%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Valuation & Rankings<\/strong><\/td>\n<\/tr>\n
Valuation<\/strong><\/td>\n12.22% undervalued<\/td>\nValuation Rank<\/strong>(?<\/a>)<\/td>\n72<\/td>\n<\/tr>\n
1-M Forecast Return<\/strong><\/td>\n-0.66%<\/td>\n1-M Forecast Return Rank<\/strong><\/td>\n13<\/td>\n<\/tr>\n
12-M Return<\/strong><\/td>\n-11.52%<\/td>\nMomentum Rank<\/strong>(?<\/a>)<\/td>\n21<\/td>\n<\/tr>\n
Sharpe Ratio<\/strong><\/td>\n0.53<\/td>\nSharpe Ratio Rank<\/strong>(?<\/a>)<\/td>\n78<\/td>\n<\/tr>\n
5-Y Avg Annual Return<\/strong><\/td>\n9.36%<\/td>\n5-Y Avg Annual Rtn Rank<\/strong><\/td>\n72<\/td>\n<\/tr>\n
Volatility<\/strong><\/td>\n17.68%<\/td>\nVolatility Rank<\/strong>(?<\/a>)<\/td>\n74<\/td>\n<\/tr>\n
Expected EPS Growth<\/strong><\/td>\n15.08%<\/td>\nEPS Growth Rank<\/strong>(?<\/a>)<\/td>\n42<\/td>\n<\/tr>\n
Market Cap (billions)<\/strong><\/td>\n167.40<\/td>\nSize Rank<\/strong><\/td>\n100<\/td>\n<\/tr>\n
Trailing P\/E Ratio<\/strong><\/td>\n15.50<\/td>\nTrailing P\/E Rank<\/strong>(?<\/a>)<\/td>\n75<\/td>\n<\/tr>\n
Forward P\/E Ratio<\/strong><\/td>\n13.47<\/td>\nForward P\/E Ratio Rank<\/strong><\/td>\n61<\/td>\n<\/tr>\n
PEG Ratio<\/strong><\/td>\n1.03<\/td>\nPEG Ratio Rank<\/strong><\/td>\n36<\/td>\n<\/tr>\n
Price\/Sales<\/strong><\/td>\n3.01<\/td>\nPrice\/Sales Rank<\/strong>(?<\/a>)<\/td>\n36<\/td>\n<\/tr>\n
Market\/Book<\/strong><\/td>\n19.19<\/td>\nMarket\/Book Rank<\/strong>(?<\/a>)<\/td>\n9<\/td>\n<\/tr>\n
Beta<\/strong><\/td>\n1.30<\/td>\nBeta Rank<\/strong><\/td>\n23<\/td>\n<\/tr>\n
Alpha<\/strong><\/td>\n-0.28<\/td>\nAlpha Rank<\/strong><\/td>\n19<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

ValuEngine.com is an Independent Research Provider (IRP), producing buy\/hold\/sell recommendations, target price, and valuations on over 5,000 US and Canadian equities every trading day.<\/strong><\/span>
\n Contact ValuEngine at (800) 381-5576 or support@valuengine.com \u00a0<\/strong><\/span>
\n Visit www.ValuEngine.com for more information<\/a><\/strong><\/span><\/p>\n

\u00a0<\/strong><\/span><\/h1>\n

ValuEngine Capital Management LLC is a Registered Investment Advisory (RIA) firm that trades client accounts using ValuEngine’s award-winning stock research. <\/strong><\/span>
\n Contact ValuEngine Capital at info@valuenginecapital.com<\/strong><\/span>
\n Visit www.ValuEngineCapital.com for more information<\/a><\/strong><\/span><\/p>\n

 <\/p>\n

Steve Hach
\nSenior Editor
\nValuEngine.com<\/em><\/strong><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

NYSE:DIS NASDAQ:ENTA NASDAQ:AXGN NASDAQ:NKTR NASDAQ:CASI This week, we provide top-five ranked VE data for our Medical Sector stocks. We take a look at our latest data on Disney $DIS and provide a free download link for our stock report on the company. VALUATION WATCH: Overvalued stocks now make up 46.74% of our stocks assigned a … Read more<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[39],"tags":[1138,769,1140,1143,1136,65,66,1137,11,762,438,62,934,927,1141,937,1142,936,9,64,68,67,63,1139],"_links":{"self":[{"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/posts\/1277"}],"collection":[{"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/comments?post=1277"}],"version-history":[{"count":3,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/posts\/1277\/revisions"}],"predecessor-version":[{"id":1279,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/posts\/1277\/revisions\/1279"}],"wp:attachment":[{"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/media?parent=1277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/categories?post=1277"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/tags?post=1277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}